| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 28, 2025 | Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore | Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside
SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ ... |
| Jun 4, 2025 | Elpis Biopharmaceuticals and Singapore General Hospital Enter Research Collaboration Agreement to Develop Next Generation Allogeneic CAR Technologies | Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma
LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific ... |
| May 7, 2025 | Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | - End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease -
- Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC -
- Two posters at ARVO describe zervimesine's role supporting retinal cell health -... |
| Apr 1, 2025 | Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes | PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results fr... |
| Mar 20, 2025 | Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB)
Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup
2025 Objective:... |
| Mar 13, 2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release ... |
| Mar 13, 2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | Conference Call and Live Audio Webcast Scheduled for March 20, 2025
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegen... |
| Mar 12, 2025 | Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing | PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by th... |
| Feb 27, 2025 | Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD | PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscrip... |
| Jan 30, 2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| Jan 30, 2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| Jan 8, 2025 | Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences | PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciar... |
| Dec 18, 2024 | Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies | - Improvements Across Measures of Behavior, Function, Cognition and Movement -
- Expediting Plans to Advance CT1812 into Late-Stage Trials -
- Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) -
- Cognition... |
| Nov 13, 2024 | Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | - CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -
- On track to report topline results from Phase 2 SHIMMER... |
| Nov 12, 2024 | Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum | PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CE... |
| Oct 31, 2024 | Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD | - Patient characteristics are consistent with other DLB studies -
PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that ... |
| Oct 29, 2024 | Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD | - Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -
- ADAS-Cog 11 scores showed 95% slowing of decline -
- MMSE scores showe... |
| Oct 22, 2024 | Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) | PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations... |
| Oct 2, 2024 | Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference | PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s pres... |
| Oct 2, 2024 | Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference | PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s pres... |
| Sep 3, 2024 | Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences | PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s p... |
| Aug 8, 2024 | Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update | - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures -
- On Track to Report Topline Results from SHIMMER Study ... |
| Aug 5, 2024 | Cognition Therapeutics to Report Second Quarter 2024 Financial Results | PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced tha... |
| Aug 5, 2024 | Cognition Therapeutics to Report Second Quarter 2024 Financial Results | - Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurode... |
| Jul 29, 2024 | Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients | - CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -
- Consistent Positive Changes Across Cognitive and Functional Measures -
- Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Modera... |
| Jul 26, 2024 | Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024 | PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on ... |
| Jul 2, 2024 | Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC | PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts s... |
| Jul 2, 2024 | Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC | PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts s... |
| May 7, 2024 | Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update | - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -
- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants -
PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therap... |
| Mar 13, 2024 | Cognition Therapeutics Announces Public Offering | Cognition Therapeutics, a company focused on treating neurodegenerative disorders, has priced a public offering of common stock at $1.75 per share. The offering is expected to raise approximately $11.5 million, with the option for additiona... |
| Mar 12, 2024 | Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock | PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today... |
| Mar 11, 2024 | Cognition Therapeutics Announces Proposed Public Offering of Common Stock | PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, toda... |
| Oct 27, 2023 | Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD | NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, i... |
| May 5, 2022 | HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists | Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells
Without Using Feeder Cells
Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy
Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells
That Circu... |
| Apr 19, 2022 | HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022 | Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer
Debut of preclinical data related to age-associated diseases
MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ... |
| Mar 28, 2022 | HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021 | $56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023
FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications
Publication of Three Pivotal Scientific Papers in Peer-Reviewed J... |
| Mar 24, 2022 | HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest | MIRAMAR, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disru... |
| Feb 3, 2022 | Third Pole Therapeutics Closes $25M Financing – eNOfit™ Wearable Device Now Ready for Clinical Trials | – eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year |
| Jan 26, 2022 | BioEclipse Therapeutics Appoints New Board Member and Names Interim CFO | MOUNTAIN VIEW, Calif., Jan. 26, 2022 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced toda... |
| Jan 24, 2022 | Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein | MIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link betwe... |
| Jan 24, 2022 | Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics' Novel Bifunctional Fusion Protein | MIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link betwe... |
| Jan 20, 2022 | HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens | MIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link betwe... |
| Jan 20, 2022 | Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development | WEXFORD, Pa., Jan. 20, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board (SA... |
| Jan 20, 2022 | HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens | Preclinical Data for HCW 9218 Included in Pivotal Scientific Paper Published in Molecular Therapy
MIRAMAR, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on dis... |
| Jan 19, 2022 | HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022 | MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrup... |
| Jan 19, 2022 | HCW Biologics' Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute's Annual PepTalk Conference 2022 | MIRAMAR, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrup... |
| Jan 6, 2022 | HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022 | MIRAMAR, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link betwee... |
| Dec 13, 2021 | HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year | MIRAMAR, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrup... |
| Dec 8, 2021 | KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors | WASHINGTON, Dec. 8, 2021 /PRNewswire/ -- KeifeRx, LLC, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced today that it has r... |
| Nov 12, 2021 | HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights | MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health sp... |
| Nov 12, 2021 | HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights | MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health sp... |
| Nov 9, 2021 | Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers | Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1/2 clinical trial to investigate tegavivint as a potential treatment for ped... |
| Oct 28, 2021 | HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer | Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company’s lead product candidate, in refractory, advanced/metastatic pancreatic cancer
MIRAMAR, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (t... |
| Oct 28, 2021 | HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer | Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company’s lead product candidate, in refractory, advanced/metastatic pancreatic cancer
MIRAMAR, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (t... |
| Oct 27, 2021 | HCW Biologics Announces Appointment of Two New Members to Board of Directors | MIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting t... |
| Oct 27, 2021 | HCW Biologics Announces Appointment of Two New Members to Board of Directors | MIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting t... |
| Sep 28, 2021 | Caring Cross : Launches Initiative To Enhance The Broad Application, Affordability, And Access To CAR-T Cell Therapy | GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, today announced its first init... |
| Sep 14, 2021 | Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc. | JUPITER, Fla., Sept. 14, 2021 /PRNewswire/ -- Jupiter Orphan Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating central nervous system (CNS) disorders and rare diseases, today announced a name change to Jupiter ... |
| Aug 31, 2021 | Cytocom, Inc. : Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc." | FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change... |
| Aug 16, 2021 | Cytocom, Inc. Reports Second Quarter 2021 Financial Results | FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, to... |
| Aug 13, 2021 | HCW Biologics : Reports Second Quarter Financial Results and Recent Business Highlights | MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting t... |
| Aug 11, 2021 | Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference | FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the compan... |
| Jul 29, 2021 | Cytocom, Inc. : Receives Commitments for $90 Million in Equity and Debt Financing | FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed... |
| Jul 28, 2021 | Cytocom Inc. Announces Completed Merger with Cleveland BioLabs | FORT COLLINS, Colo., July 28, 2021 /PRNewswire/ -- Cytocom Inc. ("Cytocom" or "Company"), a leading biopharmaceutical company creating next-generation therapies that focus on immune homeostasis, today announced the compl... |
| Jul 21, 2021 | Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications | NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the dev... |
| Jul 20, 2021 | HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering | MIRAMAR, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen h... |
| Jun 18, 2021 | KEMPHARM, INC.
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement | CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with cer... |
| Apr 13, 2021 | Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors | – Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers. |
| Mar 17, 2021 | Codagenix Expands Senior Management Team With Three New Appointments | NEW YORK, March 17, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appoi... |
| Mar 17, 2021 | Codagenix Expands Senior Management Team With Three New Appointments | NEW YORK, March 17, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appoi... |
| Mar 5, 2021 | BioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid Tumors | Mountain View, Calif., March 5, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced toda... |
| Feb 17, 2021 | Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc. | FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement o... |
| Feb 16, 2021 | Mirimus, Inc. Partners with The Pingry School to Enable COVID-19 Surveillance Testing of Faculty, Staff, and Students Using Pioneering SalivaClear Testing Platform | NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Mirimus, Inc., a leader in conducting high-volume, high-quality PCR testing, announced that since October 2020 it has worked with The Pingry School, a K-12, coeducational independent day school with c... |
| Feb 16, 2021 | Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings | Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers |
| Feb 11, 2021 | Loki Therapeutics to Present at BIO CEO & Investor Digital Conference | LONG ISLAND CITY, N.Y., Feb. 11, 2021 /PRNewswire/ -- Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics that leverage childhood vaccination recall antigens, announced today its Chief Executive Offi... |
| Cytocom Receives FDA Clearance of IND for Phase 2 Clinical Trial of CYTO-205 as Treatment for COVID-19 | FORT COLLINS, Colo., March 16, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigation... |
| Cytocom to Present at the H.C. Wainwright Global Life Sciences Conference | FORT COLLINS, Colo., March 2, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, announced today that Mike Handley, President and Chief Executive Officer, will present at the... |
| Third Pole Therapeutics Expands Board of Directors | WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Third Pole, Inc., a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced today that it has added two seasoned pharmaceutical executives... |
| Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera | JUPITER, Fla., March 4, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other... |
| NAVAN Closes Seed Funding Round – Investors include Amgen Ventures, HTGF and Hemi Ventures | NAVAN Technologies, Inc. (NAVAN), a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round le... |
